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Abstract. In the present study, we sought to elucidate the effect 
of miR-145 on glioma cell progression and its mechanisms of 
action. We examined the effects of miR-145 on proliferation 
and invasion of U87 glioma cells and on capillary tube forma-
tion. Our data show that restoration of miR-145 in U87 glioma 
cells significantly reduced their in vitro proliferation, invasion 
and angiogenesis. However, decreased miR-145 expression 
promoted U87 glioma cell proliferation, invasion and angiogen-
esis, and reduced-expression of miR-145 increased ADAM17 
and EGFR expression in U87 cells. Overexpression of miR-145 
reduced ADAM17 and EGFR expression. VEGF secretion 
and VEGF expression were decreased by increased miR-145 
expression in U87 cells and were reversed by miR-145 down-
regulation in vitro. Nude mice with intracerebral implantation 
of U87 overexpressing miR‑145 cells exhibited significantly 
reduced tumor growth and promoted survival compared with 
control groups. Taken together, these results suggest a role 
for miR-145 as a tumor suppressor which inhibits glioma cell 
proliferation, invasion and angiogenesis in vitro and reduces 
glioma growth in vivo.
Introduction
High-grade gliomas are malignant as they are highly vascu-
larized and invasive, and characterized by high incidence of 
recurrence and poor prognosis (1,2). The prognosis for patients 
with malignant gliomas has not significantly changed in recent 
years (3). Glioma cells infiltrate into the normal brain adja-
cent to the tumor causing treatment failure from conventional 
therapy, including surgery, radiotherapy and chemotherapy 
(4). Thus, median survival time has changed little and is ~15 
months (1). Brain tumors constitute the second most frequent 
cause of cancer deaths in patients <15 years of age, the third-
cause for adult men, and the fourth cause in women aged 15-34 
years (5). Malignant gliomas are highly fatal and often strike 
patients in their most productive years.
MiRNAs, a class of small, non-encoding RNAs that tran-
scriptionally or post- transcriptionally modulate the expression 
of their target genes, and have been implicated as regulatory 
molecules in various cancers from lung, breast, colon, pros-
tate, head and neck, including melanoma and glioma (6,7). 
MiRNAs may alter the functions of oncogenes and/or tumor 
suppressor genes, and therefore, impact the biological behavior 
of these cancers. miR-145 is a tumor-suppressive miRNA that 
has been recently implicated in the regulation of cell growth 
in tumor cells through targeting c-myc, EGFR, OCT4, and 
MUC1 (8-11). However, little has been reported on whether 
miR-145 is associated with glioma progression.
ADAM17 (a.k.a. TACE), is involved in the ectodomain 
shedding of multiple membrane-bound ligands and cyto-
kines, it has been implicated in diverse biological processes, 
including growth and inflammation (12). Currently, ADAM17 
is best known as the primary secretase responsible for releasing 
the soluble form of tumor necrosis factor-α (TNF-α) from 
the plasma membrane. Of particular interest, ADAM17 has 
recently been identified as the primary sheddase for multiple 
epidermal growth factor receptor (EGFR) pro-ligands (13). 
EGFR ligand-binding results in receptor self-dimerization, 
auto-phosphorylation and subsequent activation of downstream 
PI3K/AKT and Ras/MAPK/ERK signaling pathways (14-16). 
EGFR is the prototype of a family of receptors with tyrosine 
kinases that participate in the control of differentiation, prolif-
eration, and cell survival, as well as in the development of 
tumors of epidermal origin (16-19). The expression of EGFR 
is frequently upregulated in human glioma, and its overexpres-
sion correlates with poor prognosis (19).
Recently, we have demonstrated that expression of miR-145 
is significantly downregulated in glioma cells as compared 
with normal brain tissue (20). miR-145 directly targets 
ADAM17 and binds to 3' UTR of ADAM17 mRNA, decreasing 
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ADAM17 protein expression. Our present study demonstrates 
that overexpression of miR-145 inhibits glioma cell prolifera-
tion, invasion, angiogenesis in vitro, and decreases glioma cell 
growth in an animal model, possibly through the mechanism 
of miR-145-related decrease of ADAM17 and EGFR protein 
expressions via the Erk/p-Erk pathway in U87 cells.
Materials and methods
Cell line and cell culture. Human glioblastoma U87, and mouse 
brain endothelial cells were obtained from the American Type 
Culture Collection (Manassas, VA, USA). The cells were 
grown in Dulbecco's modified Eagle's medium (DMEM; 
Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal 
bovine serum, 50 U/ml penicillin, and 50 mg/ml streptomycin. 
The U87 cells were maintained in a humidified 37˚C incubator 
with 5% CO2, fed every 3 days with complete medium, and 
subcultured when confluence was reached.
Transfection of U87 cells with miR‑145 and MiRzip‑145. The 
cDNAs encoding miR-145 and cel-67 were purchased from 
Genscript (Piscataway, NJ, USA). MiRzip-145 was purchased 
from System Biosciences (Mountain View, CA, USA). 
Transfections were done with the use of Lipofectamine 2000 
(Life Technologies, Grand Island, NY, USA) according to 
the manufacturer's instructions. Briefly, 1.5x105 U87 glioma 
cells were seeded onto 6-well plate and incubated with 4 µg 
cDNA as suggested by the manufacturer. After 48 h, cells 
were selected using Puromycin (Sigma-Aldrich, St. Louis, 
MO, USA).
Modified cell lines. Modified cell lines used in this study 
were stable transfection U87 cells with miR-145 cDNA 
plasmid stable transfection (U87-miR-145), U87 glioma cells 
with negative control cel-67 plasmid (U87-cel-67), and U87 
glioma cells with miRzip-145 (targeting miR-145) plasmid 
stable transfection (U87-zip-145). The stable transfection was 
completed per the instructions of the Lipofectamine 2000 kit, 
according to the manufacturer's instructions.
Growth curve. U87 cells (1x104) were plated into each well of 
24-well plates containing DMEM with FBS at a concentra-
tion of 10%. Every 24 h medium was removed, adherent cells 
were trypsinized, and the total cell number of each well was 
quantified with the use of a hematocytometer. Cell number 
was expressed as an average of counts from three wells per 
time point per group. 
Bromodeoxyuridine incorporation assay. Cell proliferation 
was measured using BrdU incorporation assay. Forty thousand 
cells in 1,000 µl complete medium per well were placed into 
24-well plates. After 48-h incubation, the culture medium was 
removed and cells were rinsed with PBS followed by incubation 
with BrdU (25 µg/ml) for 2 h and fixed in 4% paraformalde-
hyde for 30 min at room temperature. Following fixation, cells 
were incubated with 50% formaldehyde in 2X SSC at 65˚C for 
30 min and with 2N HCl at 37˚C for 10 min. After incubation 
with 0.1 M boric acid at room temperature for 3 min, cells were 
rinsed with PBS and blocked with 1% bovine serum albumin 
at room temperature for 1 h, followed by incubation with an 
anti‑BrdU antibody overnight at 4˚C. Cells were then incu-
bated with a FITC‑conjugated secondary antibody to visualize 
BrdU positive labeled cells. Before mounting with coverslips, 
cells were incubated with 10 µg/ml of DAPI (4'-6-diamidino-
2‑phenylindole, Invitrogen) for 10 min. Four fields of cells were 
counted randomly in each well under a fluorescent microscope 
at x10 magnification. The proliferation rate was expressed as 
the percentage of BrdU positive labeled cells divided by DAPI 
labeled cells.
In vitro invasion assay. Matrigel chambers (BD Biosciences) 
were used to determine the effect of stable expression of 
miR-145 on invasiveness, according to the manufacturer's 
protocol. Cells (1x105) with stable transfection of miR-145, or 
zip-145 were plated into 6-well plates and incubated for 48 h. 
Then, glioma cells were re-suspended in 500 µl of serum-free 
medium and added to the upper chamber, while the lower 
chamber was filled with 0.5 ml of complete medium that 
served as a chemo-attractant. Cells were then incubated for 
24 h at 37˚C. After removal of cells from the upper surface 
of the membrane, cells on the lower surface of the membrane 
were stained with CellTracker™ Green (Molecular Probes, 
Eugene, OR, USA) for 30 min and fixed in 4% formaldehyde. 
Nine fields of cells were counted randomly in each well 
under a fluorescent microscope at x100 magnification. All the 
experiments were done in duplicate and results were expressed 
as mean ± SEM of three independent experiments.
Capillary‑like tube formation assay. Briefly, 0.1 ml growth 
factor reduced Matrigel (Becton-Dickinson) was added per 
well, and mouse brain endothelial cells (MBECs, 2x104 cells) 
were added and incubated in: i) regular cell culture medium 
(DMEM) for control; ii) cell culture medium from U87 only 
cell culture; iii) cell culture medium from U87 miR-145 cell 
culture; iv) cell culture medium from U87 zip‑145 for ≤3 h. 
All assays were performed in triplicates. For quantitative 
measurements of capillary tube formation, Matrigel wells were 
digitized under a 4x objective (Olympus) for measurement of 
total tube length of capillary tube formation using the MCID 
image analysis system (Imaging Research, St. Catharines, 
Canada) at 3 h. Tracks of endothelial cells organized into 
networks of cellular cords (tubes) were counted and averaged 
in randomly selected three microscopic fields. The total tube 
length was calculated by MCID software in each field. The 
tube formation index was expressed as tube length (mm) 
per field.
Western blot analysis. Cultures were rinsed with PBS and 
proteins were extracted in 500 ml RIPA lysis buffer (50 mM 
Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxy-
cholate, 1 mM EDTA, 0.1% SDS and 0.01% sodium azide, 
pH 7.4). Equal amounts of proteins, as determined by the BCA 
protocol (Pierce, Rockford, IL, USA), run on 10% Tris-glycine 
gels (Invitrogen) and then transferred to PVDF membranes 
(Bio-Rad, Hercules, CA, USA). The membranes were blocked 
with 0.1% I-Block (Applied Biosystems, Foster City, CA, 
USA) in PBS-T (0.3% Tween-20) at room temperature for 
1 h, followed by incubation with primary antibodies against 
ADAM17 (Abcam, Cambridge, MA, USA), EGFR (Cell 
Signaling, Danvers, MA, USA), Erk, p-Erk and actin (Santa 
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Cruz, Santa Cruz, CA, USA) at 4˚C overnight. The membranes 
were washed with PBS-T (0.3% Tween-20) and incubated for 
1 h at room temperature with horseradish peroxidase‑conju-
gated secondary antibodies (Bio-Rad Laboratories). Following 
washing, the specific proteins were detected using a West Pico 
chemiluminescent protein detection kit (Pierce). The experi-
ment was repeated in triplicate. The densities of the bands 
were analyzed using the Scion image software (Frederick, 
MD, USA).
TaqMan real‑time PCR analysis of miR‑145. Extraction of 
total RNA was obtained using Qiagen miRNeasy Mini isola-
tion kit (Qiagen, Valencia, CA, USA) in accordance with the 
manufacturer's instructions. To quantify the expression level 
of the miR-145 in glioma cells with either stable transfection of 
miR-145 or zip-145, TaqMan real-time PCR of miR-145 expres-
sion was carried out using TaqMan assay kits according to the 
manufacturer's protocol. The kits contain TaqMan probes to 
detect mature miRNA in a two-step RT-PCR analysis. CDNAs 
were synthesized from total RNA using miRNA-specific 
primers and the TaqMan miRNA reverse transcription (RT) 
kit, according to the manufacturer's instructions. The 15-µl 
reactions were incubated on a PCR system for 30 min at 16˚C, 
30 min at 42˚C, 5 min at 85˚C, and then held at 4˚C. All reverse 
transcriptions and no-template controls were run at the same 
time. PCR amplification was carried out using sequence-
specific primers on the Applied Biosystems 7500 real‑time 
PCR system (Applied Biosystems). The assay was carried 
out in a 96‑well optical plate at 95˚C for 10 min, followed by 
40 cycles of 95˚C for 15 sec and 60˚C for 60 sec. The threshold 
cycle (CT) data and baselines were determined using auto 
settings. U6 small RNA (RNU6B) was also identified using 
the TaqMan RNU6B assay kit for normalizing the levels of 
miR-145. Each sample that included no template was analyzed 
in triplicate.
Human glioma cell implantation in nude mice. Nude mice 
(Nu/Nu Athymic, Charles River Breeding, MA, USA) with 
body weight of 15-25 g were anesthetized with ketamine 
(80 mg/kg) and xylazine (10 mg/kg) administered intraperi-
toneally (i.p.). After fixing the mouse in a stereotaxic device, 
the scalp was retracted to expose the cranium, and a 3-4-mm 
incision was made directly down the midline. With the use of 
a drill, a 2-mm craniotomy was made on the right hemisphere 
anterior to the coronal suture. A 10-ml Hamilton syringe was 
positioned to inject tumor cells stereotactically into the right 
hemisphere - 3.5 mm depth, 1.5 mm to the right, and 1.0 mm 
anterior to the bregma. U87 cells (7.5x105), U87-cel-67, 
U87‑miR‑15, or U87‑zip‑145 were injected intracerebrally in 
a 7.5‑µl volume. The craniotomy was covered with a film of 
polyvinyl chloride glued to the surrounding intact bone and 
the incision was closed with 4-0 silk suture. Tumor volume 
was evaluated in 6‑mm paraffin sections in the tumor region 
stained with H&E. During sacrifice, mice were perfused via 
the left ventricle with heparinized saline followed by 4% para-
formaldehyde. Tumor-bearing brain was processed, placed in 
paraffin, and subsequently five equally spaced sections (6 mm 
thick) were obtained from each of the 1-mm thick blocks 
encompassing the tumor. The sections were stained with H&E 
for microscopic analysis.
Statistical analysis. Data are presented as mean and standard 
error of the mean. Statistical significance was analyzed by 
one-way ANOVA using GraphPad Prism software (version 4.0). 
P-value smaller than 0.05 (P<0.05) was considered statistically 
significant.
Results
miR‑145 expression level in human glioma cell lines. Using 
real-time RT-PCR, we compared the expression levels of 
miR-145-3p and miR-145-5p in glioma cell lines with total 
RNA from normal human astrocytes. Human astrocytes were 
obtained from ScienCell Research Laboratories. As shown 
in Fig. 1, miR-145-5p and miR-145-3p expression levels were 
significantly lower (4.2 and 6.3%) in U87 compared to total 
RNA from human astrocytes. miR-145-5p directly targets 
ADAM17 mRNA and inhibits glioma cell proliferation and 
invasion (20). These data suggest the potential therapeutic 
value of miR-145 in malignant human gliomas.
Establishment of U87 with stable expression of miR‑145 and 
its inhibitor zip‑145. We transfected U87 glioma cells with 
plasmids encoding miR-145 or zip-145, then added puromycin 
for high-expression clones. To determine miR-145 expression 
level with stable transfection of miR-145 and its inhibitor 
zip-145, Taqman real-time PCR analysis of miR-145 level was 
used to measure and confirm miR‑145, zip‑145 versus control 
U87 cells. As shown in Fig. 1, miR-145 expression level was 
significantly elevated (53.8‑fold) in U87‑145 cells compared 
with levels in control U87 cells. As for miR-145 overexpres-
sion in U87-zip-145 glioma cells, Fig. 1 shows that miR-145 
expression level was significantly decreased to 0.4% compared 
to control U87 cells. The data suggested that stable transfec-
tion of miR-145 and zip-145 was established in the U87 cell 
lines.
miR‑145 decreases cell growth in U87 glioma cells. U87 cells 
transfected with miR-145 plasmid and control U87 cells 
were harvested and seeded at a density of 1x104 cells/well 
in 24‑well plates. The total cell number was quantified daily 
with a hematocytometer. Our data showed that overexpres-
sion of miR‑145 significantly decreased the growth rate of 
U87 cells after 5 days culture (Fig. 2). Downregulation of 
miR‑145 significantly increased the growth rate of U87 cells 
from 13.2 to 20.3% compared to control. We employed an 
additional method, the BrdU incorporation assay, to further 
test miR-145-mediated growth inhibition of glioma cells using 
miR-145 plasmid transfected U87 clones (Fig. 2). After 48 h of 
culture, miR-145 cells showed a 47.7% decrease in BrdU incor-
poration as compared with control. At the same time, we tested 
the downregulation of miR-145 on glioma cell proliferation. 
As compared with control U87 cells, miR-145 downregulation 
evidently increased BrdU incorporation after 48 h of culture 
by 145.4% as compared with the control group.
Overexpression of miR‑145 inhibits glioma cell invasive‑
ness. We employed the Matrigel invasion assay to test if 
overexpressing miR-145 affects glioma cell invasiveness. 
Invasive cells were measured at 24 h after addition of cells 
into the upper chamber. miR‑145 overexpression significantly 
LU et al:  miR-145 INHIBITS GLIOMA CELL MALIGNANCY AND INCREASES TUMOR-BEARING MOUSE SURVIVAL1034
decreased cell invasion by 63.6% in U87 (Fig. 3). However, 
the invasiveness of miRzip-145 transfected glioma cells was 
significantly increased by 1.53‑fold compared to control cells. 
The in vitro invasion assay data indicated that the invasiveness 
of U87 glioma cells is related to miR-145 expression levels, and 
increase of miR-145 decreases the invasiveness in U87 cells.
Overexpression of miR‑145 inhibits tube formation in cultured 
mouse brain endothelial cells. To test the effect of miR-145 
expression upon glioma-induced angiogenesis, we performed 
a tube-formation assay of mouse brain endothelial cells 
(MBECs) in vitro. As shown in Fig. 4, culture medium from 
U87 glioma overexpressing miR-145 significantly reduced 
capillary tube formation of mouse brain endothelial cells by 
34.55% when compared to control U87 media. While down-
regulation of miR‑145 medium showed a significant 1.28‑fold 
increase in MBECs capillary tube formation compared to 
control medium. These results suggest that miR-145 in glioma 
cells promotes angiogenesis.
Overexpression of miR‑145 decreases VEGF in mRNA and 
soluble protein release levels. Real-time PCR was employed 
to measure VEGF mRNA expression level in U87 miR-145, 
U87 zip-145, and control U87 glioma cells (Fig. 4). VEGF 
expression level was significantly increased (3.16‑fold) in U87 
zip‑145 cells, and was significantly decreased by 95.13% in 
U87 miR-145 cells compared to control cells. These results 
indicate that miR-145 regulates VEGF mRNA expression.
VEGF soluble protein release showed the same profile 
as mRNA levels in all experimental groups. miR-145, 
zip‑145, control U87 cells were cultured under 37˚C for 24 h 
to attached to the bottom of the 6-well plate, respectively. 
Following complete removal of medium 24 h later, glioma 
cells were rinsed by PBS and serum-free medium was added 
Figure 1. miR-145 expression levels in glioma cells. (A) Total RNA was isolated from normal human astroyctes and U87 gliomas. Real-time PCR was 
performed to analyze the expression ofmiR-145-3p and miR-145-5p. The relative expression of miR-145-3p and-5p was expressed as the ratio of the expression 
level of normal human astrocytes. *P<0.05, as compared with norml human astrocytes. (B) U87 glioma cells were stably transfected with miR-145 and zip-145, 
and collected for real‑time RT‑PCR. Stable transfection of miR‑145 significantly increased miR‑145‑5p in U87, as compared with non‑transfected cells. 
However, compared to non‑transfected U87 cells, stable transfection of zip‑145 significantly decreased miR‑145‑5p. *P<0.05 versus U87 glioma cells without 
transfection of miR-145 or zip-145.
  A
  A   B
Figure 2. miR-145 inhibits glioma cell growth and proliferation in vitro. Overexpression decreased glioma proliferation. Downregulation of miR-145 by 
zip-145 increased glioma cell proliferation. (A) Growth curve; (B) BrdU incorporation assay for 48 h. *P<0.05 versus control.
  B
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for another 24 h. Culture medium was then collected for anal-
ysis of soluble VEGF release from glioma cells (Fig. 4). High 
miR-145 expression decreased to 62.4% the VEGF release to 
supernatant by U87 miR-145, and low expression of miR-145 
increased VEGF release to 2.4-fold by U87 zip-145.
ADAM17, EGFR, and Erk phosphorylation in miR‑145 over‑
expressing cell lines. To test the hypothesis that ADAM17/
EGFR/ERK/p-ERK contribute to the miR-145 effect on 
glioma cells, western blot assay was employed (Fig. 5). The 
data showed that miR-145 overexpressing U87 cells have 
Figure 3. Effect of miR-145 expression on glioma cell invasiveness in vitro. The 24-h in vitro Matrigel invasion assay revealed that miR-145 overexpression 
decreased glioma cell invasiveness by 63.6% compared to control cells, and the miR‑145 downregulation significantly increased invasiveness by 1.53‑fold 
compared to control cells. In vitro invasion assay indicated that the invasiveness of U87 glioma cells is correlated to miR-145 levels. *P<0.05 versus control.
Figure 4. miR-145 overexpression in glioma cells inhibits tube formation in 
MBECs. Culture medium from U87 miR-145 cells decreased MBECs capillary 
tube formation by 34.55% compared to control medium. Medium from U87 
zip-145 cells promoted capillary tube formation by 1.28-fold compared to con-
trol. As compared with medium only, U87 conditioned medium increased the 
tube formation in MBECs. Overexpression of miR‑145 signficantly decreased 
VEGF expression in U87 miR-145 cells and soluble VEGF release after 24 h. 
While zip‑145 significantly promoted VEGF expression in U87 zip‑145 cells 
and soluble VEGF release. *P<0.05 versus control; **P<0.05 versus control.
Figure 5. Effect of miR-145 overexpression or downregulation on ADAM17/
EGFR/ERK activation in U87 cells. miR-145 was reported to directly target 
ADAM17 and EGFR. ADAM17 and EGFR expression showed a significant 
decrease in U87 miR‑145 cells and a significant increase in U87 zip‑145 cells. 
Expression of p-Erk showed the same trend as ADAM17/EGFR, but expres-
sion of Erk was not significantly affected by miR‑145 expression levels.
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lower expression of ADAM17 and EGFR, respectively, in 
total protein levels, and lower phosphorylation state of Erk as 
compared with control groups. Furthermore, low expression of 
miR-145 in glioma cells was correlated to increased ADAM17 
and EGFR expression. These data suggest that miR-145 
significantly contribute to the pathways known to promote 
glioma cell malignancy.
miR‑145 inhibits U87 glioma growth in nude mice. MiR145-
overexpressing U87 glioma cells were transfected with 
negative plasmid cel-67, and: i) control; ii) cel-67; iii) miR-145; 
and iv) zip‑145 U87 glioma cells were injected stereotactically 
(5x105 cells/mouse) at a depth of 3.5 mm, 1.5 mm to the right 
of midline, and 1.0 mm anterior to the bregma. Animals were 
sacrificed at 30 days after tumor implantation. Tumor‑bearing 
brain was processed, placed in paraffin, and subsequently 
seven equally spaced, 6 µm sections, were obtained from each 
of the 1-mm blocks encompassing the tumor. The sections 
were stained with H&E for light microscopic examination and 
analysis. After 30 days, miR-145 transfected U87 cells showed 
a significant decrease in tumor volume (Fig. 6) in nude mice 
compared to control cells and parent glioma cells transfected 
with cel-67. As shown in Fig. 6, zip-145 transfected U87 cells 
grew to form a solid tumor and showed no significant increase 
in tumor volume in comparison with control. The nude mice 
with U87 zip-145 cell implantation died 14 days after implanta-
tion. These data indicate that miR‑145 significantly contributes 
to glioma xenograph growth, and suggests overexpression of 
miR-145 may have therapeutic antitumor effects for glioma.
Discussion
Glioblastoma is the most common primary brain tumor in 
adults. Almost all high-grade gliomas will invariably recur due 
to their extensive invasion into the surrounding brain tissue 
supported by their high capacity of neovascularization (21). 
These features cause treatment failure and have a very high 
mortality rate by conventional therapies. ADAMs are an 
important family of proteins upregulated in many cancers 
including glioma (22,23). miR-145 has been reported to target 
and regulate ADAM17, an important ADAM family member 
(20,24). In addition, accumulated evidence showed that the 
non-coding miRNAs have multi-function on gene regulation 
during tumor progression (25).
In the present study, the U87 human glioblastoma cell 
line was employed to investigate to the effect of miR-145 on 
glioma cell proliferation, invasion, and angiogenesis in vitro. 
Overexpression and downregulation of miR-145 were estab-
lished with transfection of miR-145 and zip-145 plasmids, 
respectively. Growth curve and BrdU incorporation assays 
were employed to examine the effect of miR-145 on U87 
glioma cell proliferation. Our data demonstrate that miR-145 
decreases U87 glioma cell proliferation. Decrease of miR-145 
by zip‑145 significantly increased tumor cell proliferation. 
These data suggest that miR-145 plays a key role in U87 cell 
malignancy. We used Matrigel invasion assays to assess the 
ability of glioma cells to penetrate the ECM. Our data showed 
that the invasion potential of U87 cells is decreased by miR-145 
overexpression, and increased by miR-145 downregulation.
Neovascularization plays critical roles in the process 
of embryo development, tissue differentiation and repair, 
inflammatory diseases, and tumor growth and metastasis 
(26,27). During the angiogenic process, endothelial cells 
digest the basement membrane of the vessel, migrate through 
the membrane while they proliferate in number, form a new 
vessel lumen and then sprout into a new vessel branch (28). 
Proliferation and growth of tumor cells consume oxygen in 
solid tumors. The hypoxia and necrosis resulting from rapid 
growth triggers the angiogenic switch out of the vascular 
quiescent state, which subsequently supports tumor progres-
sion (29). The initiation of newly formed tumor vessels also 
known as neovascularization or angiogenesis requires pro-
angiogenic growth factors including vascular endothelial 
growth factor (VEGF) and related molecules. VEGF can be 
triggered by extracellular signals such as transforming growth 
factor α (TGF-α) and hypoxia-inducible factor 1-α (HIF-α), 
and internal genetic change (29,30). ADAM17 and EGFR 
increase the expression of HIF-α, and HIF-α then activates 
Figure 6. The expression level of miR‑145 is related to U87 glioma cell growth in nude mice. U87 miR‑145 showed significant decrease in tumor volume 
(36.25 vs 1.25 mm3, *P<0.05) in nude mice compared to control glioma cells. Zip‑145 transfected cells showed no significant growth rate as compared with 
their parent cells. n=6 nude mice/group; *P<0.05 versus control.
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VEGF and VEGFR to stimulate tumor angiogenesis (22,31). 
To address the function of miR-145 on glioma angiogenesis, 
we further tested VEGF expression in U87 cells and angio-
genesis in vitro with mouse brain endothelial cells cultured in 
supernatant from U87 cells. Real-time PCR, soluble protein, 
and tube formation assays demonstrated that high expression 
of miR-145 leads to a decrease in gene, protein and functional 
levels of VEGF. VEGF plays an important role in glioma 
progression. An in vitro capillary tube formation assay was 
employed to determine the effect of miR-145 on angiogenesis. 
Our data suggest that miR-145 decreased capillary-like tube 
formation. However, downregulation of miR-145 reverses the 
capacity of tube formation that was associated with lowered 
VEGF expression. Therefore, our data suggest downregulation 
of VEGF expression may be one of mechanisms by which 
miR-145 inhibits angiogenesis. We found that miR-145 expres-
sion was inversely correlated with VEGF mRNA, in addition 
to VEGF protein. This suggests that the effect of miR-145 upon 
VEGF may be indirect, rather than via translational inhibition. 
It is also likely that other factors or pathways are involved in 
the regulation of neovascularization. Therefore, further inves-
tigation of other signaling factors or pathways is warranted.
In our in vivo study, the data indicate that miR-145 is a 
growth inhibitor in U87 human glioma progression. Stable 
transfection with a plasmid encoding miR-145 leads to inhi-
bition of the malignant phenotype. miR-145 overexpression 
decreased the rate of tumor growth in U87-miR-145 glioma 
bearing nude mice as compared with those parent tumor 
control and negative tumor control. Downregulation of 
miR-145 promotes tumor invasion and tumor growth. These 
data confirmed our in vitro result that increased miR-145 
expression decreases glioma proliferation.
ADAM17 is a primary sheddase for multiple EGFR pro-
ligands, such as HB-EGF and TGF-α (13,32). EGFR can be 
activated by its ligands including EGF, TGF-α, amphiregulin, 
and betacelluin (14,33). It is the first identified receptor tyro-
sine kinase (34). EGFR is amplified and overexpressed in 
tumors of many tissues (35-37). EGFR and its downstream 
signaling pathway is a key regulator of cell proliferation 
and it is frequently deregulated in cancer (38,39). EGFR 
ligand-binding results in receptor self-dimerization, auto-
phosphorylation, and subsequent activation of downstream 
PI3K/AKT and Ras/MAPK pathways, which are responsible 
for the malignant phenotype (14,15). Furthermore, we exam-
ined the mechanisms by which ADAM17/EGFR/MAPK/
ERK pathway contributed to miR-145-induced inhibition on 
glioma proliferation, invasion, and angiogenesis after trans-
fection of miR-145. High expression of miR-145 resulted in 
a significant decrease in U87 cell proliferation, invasion and 
angiogenesis. Coincidentally, miR-145 overexpression deacti-
vated ADAM17/EGFR/ERK in vitro, and downregulation of 
miR-145 increased ADAM17/EGFR/ERK activation. These 
data further indicate that miR-145 overexpression contributes 
to reduction of tumor progression through deactivation of the 
ADAM17/EGFR/ERK pathway.
Acknowledgements
This study was supported by the National Institutes of 
Health grant RO1 CA12944 (F.J.). We thank Cindi Roberts 
and Qinge Lu for technical assistance on histology. The 
content is solely the responsibility of the authors and does 
not necessarily represent the official view of the National 
Institutes of Health.
References
  1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy 
plus concomitant and adjuvant temozolomide for glioblastoma. 
N Engl J Med 352: 987-996, 2005.
  2. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO 
classification of tumours of the central nervous system. Acta 
Neuropathol 114: 97-109, 2007.
  3. Beauchesne P: Fotemustine: a third-generation nitrosourea for 
the treatment of recurrent malignant gliomas. Cancers (Basel) 4: 
77-87, 2012.
  4. Tanase CP, Enciu AM, Mihai S, Neagu AI, Calenic B and 
Cruceru ML: Anti-cancer therapies in high grade gliomas. Curr 
Proteomics 10: 246-260, 2013.
  5. Wingo PA, Tong T and Bolden S: Cancer statistics, 1995. CA 
Cancer J Clin 45: 8-30, 1995.
  6. Esteller M: Non-coding RNAs in human disease. Nat Rev Genet 
12: 861-874, 2011.
  7. Cheng Q, Yi B, Wang A and Jiang X: Exploring and exploiting 
the fundamental role of microRNAs in tumor pathogenesis. 
Onco Targets Ther 6: 1675-1684, 2013.
  8. Hu J, Guo H, Li H, et al: MiR-145 regulates epithelial to mesen-
chymal transition of breast cancer cells by targeting Oct4. PLoS 
One 7: e45965, 2012.
  9. Wang F, Xia J, Wang N and Zong H: miR-145 inhibits prolif-
eration and invasion of esophageal squamous cell carcinoma 
in part by targeting c-Myc. Onkologie 36: 754-758, 2013.
10. Cho WC, Chow AS and Au JS: MiR-145 inhibits cell proliferation 
of human lung adenocarcinoma by targeting EGFR and NUDT1. 
RNA Biol 8: 125-131, 2011.
11. Sachdeva M and Mo YY: MicroRNA-145 suppresses cell 
invasion and metastasis by directly targeting mucin 1. Cancer 
Res 70: 378-387, 2010.
12. Seals DF and Courtneidge SA: The ADAMs family of metallo-
proteases: multidomain proteins with multiple functions. Genes 
Dev 17: 7-30, 2003.
13. Lee DC, Sunnarborg SW, Hinkle CL, et al: TACE/ADAM17 
processing of EGFR ligands indicates a role as a physiological 
convertase. Ann NY Acad Sci 995: 22-38, 2003.
14. Wells A: EGF receptor. Int J Biochem Cell Biol 31: 637-643, 
1999.
15. Lal A, Glazer CA, Martinson HM, et al: Mutant epidermal 
growth factor receptor up-regulates molecular effectors of tumor 
invasion. Cancer Res 62: 3335-3339, 2002.
16. Datta SR, Brunet A and Greenberg ME: Cellular survival: a play 
in three Akts. Genes Dev 13: 2905-2927, 1999.
17. Maher EA, Furnari FB, Bachoo RM, et al: Malignant glioma: 
genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 
2001.
18. Wechsler-Reya R and Scott MP: The developmental biology of 
brain tumors. Annu Rev Neurosci 24: 385-428, 2001.
19. Mineo JF, Quintin-Roue I, Lucas B, Buburusan V and Besson G: 
Glioblastomas: clinical study and search for prognostic factors. 
Neurochirurgie 48: 500-509, 2002 (In French).
20. Lu Y, Chopp M, Zheng X, Katakowski M, Buller B and Jiang F: 
MiR-145 reduces ADAM17 expression and inhibits in vitro 
migration and invasion of glioma cells. Oncol Rep 29: 67-72, 
2013.
21. Nieto-Sampedro M, Valle-Argos B, Gomez-Nicola D, Fernandez-
Mayoralas A and Nieto-Diaz M: Inhibitors of glioma growth 
that reveal the tumour to the immune system. Clin Med Insights 
Oncol 5: 265-314, 2011.
22. Zheng X, Jiang F, Katakowski M, Lu Y and Chopp M: ADAM17 
promotes glioma cell malignant phenotype. Mol Carcinog 51: 
150-164, 2012.
23. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE and 
Chopp M: ADAM17 promotes breast cancer cell malignant 
phenotype through EGFR-PI3K-AKT activation. Cancer Biol 
Ther 8: 1045-1054, 2009.
24. Doberstein K, Steinmeyer N, Hartmetz AK, et al: MicroRNA-
145 targets the metalloprotease ADAM17 and is suppressed in 
renal cell carcinoma patients. Neoplasia 15: 218-230, 2013.
LU et al:  miR-145 INHIBITS GLIOMA CELL MALIGNANCY AND INCREASES TUMOR-BEARING MOUSE SURVIVAL1038
25. Ling H, Fabbri M and Calin GA: MicroRNAs and other non-
coding RNAs as targets for anticancer drug development. Nat 
Rev Drug Discov 12: 847-865, 2013.
26. Furuya M, Nishiyama M, Kasuya Y, Kimura S and Ishikura H: 
Pathophysiology of tumor neovascularization. Vasc Health Risk 
Manag 1: 277-290, 2005.
27. Folkman J: Angiogenesis. Annu Rev Med 57: 1-18, 2006.
28. Ausprunk DH and Folkman J: Migration and proliferation of 
endothelial cells in preformed and newly formed blood vessels 
during tumor angiogenesis. Microvasc Res 14: 53-65, 1977.
29. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic 
switch. Nat Rev Cancer 3: 401-410, 2003.
30. Perry BN and Arbiser JL: The duality of angiogenesis: impli-
cations for therapy of human disease. J Invest Dermatol 126: 
2160-2166, 2006.
31. Goldman CK, Kim J, Wong WL, King V, Brock T and 
Gillespie GY: Epidermal growth factor stimulates vascular endo-
thelial growth factor production by human malignant glioma 
cells: a model of glioblastoma multiforme pathophysiology. Mol 
Biol Cell 4: 121-133, 1993.
32. Ruhe JE, Streit S, Hart S and Ullrich A: EGFR signaling leads 
to downregulation of PTP-LAR via TACE-mediated proteolytic 
processing. Cell Signal 18: 1515-1527, 2006.
33. Mendelsohn J and Baselga J: The EGF receptor family as targets 
for cancer therapy. Oncogene 19: 6550-6565, 2000.
34. Ullrich A, Coussens L, Hayflick JS, et al: Human epidermal 
growth factor receptor cDNA sequence and aberrant expres-
sion of the amplified gene in A431 epidermoid carcinoma cells. 
Nature 309: 418-425, 1984.
35. Chaffanet M, Chauvin C, Laine M, et al: EGF receptor amplifica-
tion and expression in human brain tumours. Eur J Cancer 28: 
11-17, 1992.
36. Horak E, Smith K, Bromley L, et al: Mutant p53, EGF receptor 
and c-erbB-2 expression in human breast cancer. Oncogene 6: 
2277-2284, 1991.
37. Haas-Kogan DA, Prados MD, Lamborn KR, Tihan T, Berger MS 
and Stokoe D: Biomarkers to predict response to epidermal 
growth factor receptor inhibitors. Cell Cycle 4: 1369-1372, 
2005.
38. Kenny PA: Three-dimensional extracellular matrix culture 
models of EGFR signalling and drug response. Biochem Soc 
Trans 35: 665-668, 2007.
39. Kenny PA: TACE: a new target in epidermal growth factor 
receptor dependent tumors. Differentiation 75: 800-808, 2007.
